Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) Director Casey Tansey acquired 16,441 shares of Mobia Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $12.07 per share, with a total value of $198,442.87. Following the purchase, the director owned 318,332 shares in the company, valued at $3,842,267.24. The trade was a 5.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Mobia Medical Price Performance
Mobia Medical stock opened at $10.95 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80. The firm has a market capitalization of $364.54 million and a P/E ratio of -0.54. Mobia Medical, Inc. has a one year low of $10.19 and a one year high of $15.29. The stock's fifty day simple moving average is $12.35.
Mobia Medical (NASDAQ:MOBI - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. Mobia Medical's revenue for the quarter was up 102.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Mobia Medical, Inc. will post -2.76 earnings per share for the current year.
Analyst Upgrades and Downgrades
MOBI has been the topic of several analyst reports. Zacks Research upgraded Mobia Medical to a "hold" rating in a report on Wednesday, June 3rd. The Goldman Sachs Group began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 price objective for the company. BTIG Research reaffirmed a "buy" rating and set a $19.00 price objective on shares of Mobia Medical in a report on Wednesday, August 12th. Wolfe Research began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued an "outperform" rating on the stock. Finally, Weiss Ratings initiated coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They issued a "sell (e-)" rating on the stock. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Mobia Medical presently has an average rating of "Moderate Buy" and an average price target of $20.75.
Get Our Latest Report on MOBI
Mobia Medical Company Profile
(
Get Free Report)
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
